1. Home
  2. NGNE vs OLMA Comparison

NGNE vs OLMA Comparison

Compare NGNE & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NGNE
  • OLMA
  • Stock Information
  • Founded
  • NGNE 2003
  • OLMA 2006
  • Country
  • NGNE United States
  • OLMA United States
  • Employees
  • NGNE N/A
  • OLMA N/A
  • Industry
  • NGNE Biotechnology: Pharmaceutical Preparations
  • OLMA Biotechnology: Pharmaceutical Preparations
  • Sector
  • NGNE Health Care
  • OLMA Health Care
  • Exchange
  • NGNE Nasdaq
  • OLMA Nasdaq
  • Market Cap
  • NGNE 325.3M
  • OLMA 378.9M
  • IPO Year
  • NGNE N/A
  • OLMA 2020
  • Fundamental
  • Price
  • NGNE $18.48
  • OLMA $5.46
  • Analyst Decision
  • NGNE Strong Buy
  • OLMA Strong Buy
  • Analyst Count
  • NGNE 7
  • OLMA 5
  • Target Price
  • NGNE $41.86
  • OLMA $24.00
  • AVG Volume (30 Days)
  • NGNE 110.1K
  • OLMA 450.7K
  • Earning Date
  • NGNE 08-11-2025
  • OLMA 08-11-2025
  • Dividend Yield
  • NGNE N/A
  • OLMA N/A
  • EPS Growth
  • NGNE N/A
  • OLMA N/A
  • EPS
  • NGNE N/A
  • OLMA N/A
  • Revenue
  • NGNE N/A
  • OLMA N/A
  • Revenue This Year
  • NGNE N/A
  • OLMA N/A
  • Revenue Next Year
  • NGNE N/A
  • OLMA N/A
  • P/E Ratio
  • NGNE N/A
  • OLMA N/A
  • Revenue Growth
  • NGNE N/A
  • OLMA N/A
  • 52 Week Low
  • NGNE $6.88
  • OLMA $2.86
  • 52 Week High
  • NGNE $74.49
  • OLMA $13.93
  • Technical
  • Relative Strength Index (RSI)
  • NGNE 35.93
  • OLMA 54.42
  • Support Level
  • NGNE $19.59
  • OLMA $5.54
  • Resistance Level
  • NGNE $20.46
  • OLMA $5.85
  • Average True Range (ATR)
  • NGNE 1.23
  • OLMA 0.30
  • MACD
  • NGNE -0.20
  • OLMA -0.01
  • Stochastic Oscillator
  • NGNE 13.37
  • OLMA 51.79

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

About OLMA Olema Pharmaceuticals Inc.

Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.

Share on Social Networks: